Introgen Therapeutics reports advances in RPR/INGN 201 clinical program for treatment of advanced cancers

Results from studies presented at annual ASCO meeting

New Orleans, LA, May 23, 2000 - Introgen Therapeutics presented data from clinical studies on the safety, transfer and expression of RPR/INGN 201 (Adenoviral p53) in three Phase I clinical studies for the treatment of bronchioalveolar cell lung carcinoma (BAC), ovarian cancer and recurrent glioblastomas at the 36th American Society of Clinical Oncology (ASCO) Annual Meeting in New Orleans, Louisiana. These studies are the subject of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) of the US National Institutes of Health (NIH) previously announced by Introgen Therapeutics and its corporate partner for its p53 program, Aventis Pharmaceuticals.

The first report, titled "A Phase I Trial of Ad p53 for Ovarian Cancer Patients: Correlation with p53 & Anti-Adenovirus," is based on research conducted by Judith Wolf, M.D., and her colleagues at The University of Texas M. D. Anderson Cancer Center. The study was designed to determine the maximum tolerable dose of adenoviral p53, administered intraperitoneally, for ovarian cancer patients and found that the therapy is well tolerated for this patient group at the administered doses.

The second report, titled "Phase I Trial of Adenovirus p53 in Bronchioalveolar Cell Lung Carcinoma Administered by Bronchoalveolar Lavage," is based on research conducted by Samir Kubba, M.D., and colleagues at The Vanderbilt Cancer Center and The University of Wisconsin Cancer Center. This study utilized a direct administration to the lower airways. Symptomatic improvement and improved lung function was reported in some patients.

The third report, titled "Preliminary Results of a Phase I Clinical Trial Of Adenovirus-Mediated p53 Gene Therapy for Recurrent Gliomas: Biological Studies," is based on research conducted by Frederick F. Lang, Assistant Professor of Neurosurgery, and colleagues at The U

Contact: Lora Pike
Noonan/Russo Communications

Page: 1 2

Related biology news :

1. Introgens gene drug demonstrates tumor growth control
2. New family of 10 cancer related genes discovered by NCI, University of Texas and M.D. Anderson researchers; licensed by Introgen
3. Introgen publishes preclinical findings demonstrating the potent anti-tumor properties of INGN 241 study featured on the cover of Molecular Medicine
4. Introgen Therapeutics reports progress in gene therapy studies at annual ASCO meeting
5. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
6. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
7. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
8. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
9. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
10. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
11. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound

Post Your Comments:

(Date:7/2/2020)... (PRWEB) , ... July 01, 2020 , ... ... presented its phase 1a findings of Neihulizumab, a biologic for the treatment of ... June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson ...
(Date:6/28/2020)... BASEL, Switzerland (PRWEB) , ... ... ... leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that ... oncology company developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... healthcare, and Renovagen Ltd, a UK supplier and manufacturer of innovative portable renewable ... testing operations in the fight against the COVID-19 pandemic in Zambia. , One ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... (PRWEB) , ... June 29, 2020 , ... ... year to date growth of 40% in 2020, despite many obstacles created as ... MedShift aims to increase revenue for its partnered medical practices and medical manufacturers ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. ... today announced the company has entered a license agreement with Roswell Park Comprehensive ... globally exclusive rights to Roswell Park intellectual property surrounding a novel medical device ...
(Date:6/23/2020)... YORK (PRWEB) , ... June 22, 2020 , ... ... its lead glutamine antagonist, DRP-104, will be presented June 22-24 during the American ... effects of DRP-104; and, the other profiles the potent, consistent single agent activity ...
(Date:6/11/2020)... GREENBELT, Md. (PRWEB) , ... June 09, 2020 ... ... announced today the release of the NEON Micro-Tracer Solution, a highly ... to the COVID-19 virus in the workplace. Contact tracing, a core disease control ...
Breaking Biology Technology:
Cached News: